Evidence map›Paper›PMID 22189047›Full record

ReviewLancet (London, England)2012

Major depressive disorder: new clinical, neurobiological, and treatment perspectives.

David J Kupfer, Ellen Frank, Mary L Phillips

6 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Lancet (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 359 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
359citing papers in PubMed, 11 pooled it
35.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03742557 phase3unknown statusnot on this mapstarted 2018, after this paper: background citation

Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation

TypeinterventionalSponsorNational Institute of Neurology and Neurosurgery, MexicoRan2018 to 2020Enrolled30ConditionsTreatment Resistant DepressionArmsKetamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV
NCT03748446 early_phase1active not recruitingnot on this mapstarted 2019, after this paper: background citation

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

TypeinterventionalSponsorMassachusetts General HospitalRan2019 to 2026Enrolled20ConditionsMajor Depressive Disorder, Bipolar DepressionArmsXenon, Nitrogen gas
NCT04780152 phase2 / phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics

TypeinterventionalSponsorEl Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco SuarezRan2021 to 2022Enrolled172ConditionsMajor Depressive DisorderArmsTranscranial Direct Current Stimulation, Placebo-simulation of transcranial direct current stimulation, Fluoxetine Tablets
NCT05327387 narecruitingnot on this mapstarted 2022, after this paper: background citation

Model-based Electrical Brain Stimulation

TypeinterventionalSponsorUniversity of Southern CaliforniaRan2022 to 2026Enrolled25ConditionsMedication Refractory Epilepsy Patients With Electrodes Already Implanted Based on Clinical Criteria for Standard MonitoringArmsmodel-based electrical brain stimulation
NCT05441969 recruitingnot on this mapstarted 2020, after this paper: background citation

In Vivo Cortical Excitability Modulation in Major Depressive Disorder

TypeobservationalSponsorFundacao ChampalimaudRan2020 to 2025Enrolled90ConditionsMajor Depressive DisorderArmsNo intervention/expousure
NCT06490965 narecruitingnot on this mapstarted 2024, after this paper: background citation

Improving Obsessive-compulsive Disorder Treatments: from Lesions to Neuromodulation Targets

TypeinterventionalSponsorFundacao ChampalimaudRan2024 to 2026Enrolled32ConditionsObsessive-Compulsive DisorderArmsRepetitive Transcranial Magnetic Stimulation, Neuronavigation, Magnetic Resonance Imaging
3 · Its place in the literature

Who cites it

359 citing papers in PubMed, 11 syntheses or guidelines pooled it, 865 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Meta-analysis of cortical thickness abnormalities in medication-free patients with major depressive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

299 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

David J KupferUniversity of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, PA, USA. Kupferdj@upmc.edu
Ellen Frank
Mary L Phillips
University of Pittsburgh Medical Center · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Depression: The Search for Treatment-Relevant PhenotypesR01MH065376 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRANK, ELLEN · 2003 to 2009
$4.0M
Reducing Medical Risks in Individuals with Bipolar DisorderR01MH081003 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KUPFER, DAVID J · 2008 to 2012
$3.1M
Toward the identification of biomarkers of bipolar disorderR01MH076971 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PHILLIPS, MARY LOUISE · 2007 to 2011
$2.1M
NCATS NIH HHS UL1 TR000005NIMH NIH HHS MH065376NIMH NIH HHS MH076971NIMH NIH HHS MH081003NIMH NIH HHS R01 MH065376NIMH NIH HHS R01 MH076971NIMH NIH HHS R01 MH081003
6 · The paper itself

Abstract

In this Seminar we discuss developments from the past 5 years in the diagnosis, neurobiology, and treatment of major depressive disorder. For diagnosis, psychiatric and medical comorbidity have been emphasised as important factors in improving the appropriate assessment and management of depression. Advances in neurobiology have also increased, and we aim to indicate genetic, molecular, and neuroimaging studies that are relevant for assessment and treatment selection of this disorder. Further studies of depression-specific psychotherapies, the continued application of antidepressants, the development of new treatment compounds, and the status of new somatic treatments are also discussed. We address two treatment-related issues: suicide risk with selective serotonin reuptake inhibitors, and the safety of antidepressants in pregnancy. Although clear advances have been made, no fully satisfactory treatments for major depression are available.

Indexed as

Antidepressive AgentsGenome-Wide Association StudyHallucinationsHumansMajor Depressive DisorderNeuroimagingPsychotherapySchizophrenia, ParanoidAntidepressive Agents

Identifiers

PMID22189047
PMCPMC3397431
OpenAlexW2076277579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.